REGN 2810

Drug Profile

REGN 2810

Alternative Names: PD-1 protein inhibitor - Regeneron; REGN2810; SAR 439684

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Regeneron Pharmaceuticals; Sanofi
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Squamous cell cancer
  • Phase I B cell lymphoma; Cancer; Lymphoma; Malignant melanoma

Most Recent Events

  • 10 Apr 2017 Phase-I clinical trials in Malignant melanoma (First-line therapy, Late-stage disease, Inoperable/Unresectable) in South Korea, United Kingdom (Parenteral) (NCT03002376)
  • 27 Mar 2017 Regeneron Pharmaceuticals plans a phase III trial for Non-small cell lung cancer (Metastatic disease, First-line therapy, Late-stage disease) (NCT03088540)
  • 10 Feb 2017 Regeneron plans phase II trials in Non-small cell lung cancer and Basal cell cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top